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Background: To evaluate the efficacy and safety of concurrent chemo-radiotherapy with weekly nedaplatin for the
treatment of advanced squamous cell carcinoma of the uterine cervix.
Methods: Patients with stage Ib2 to IIIb squamous cell carcinoma of the uterine cervix were treated with
concurrent radiotherapy and chemotherapy. The radiotherapy regimen included external beam radiation therapy
(45–50.4Gy/25-28 fractions with central shielding after 30.6Gy) and high-dose-rate brachytherapy irradiation
(35-49Gy/5-7 fractions to point A). The chemotherapy regimen was weekly intravenous infusion of nedaplatin
(30 mg/m2, once weekly, 180 mg/m2 for 6 weeks).
Results: Thirty patients were enrolled in this study from April 2010 to October 2010. The median age was 50.5 years
(34–62). Three patients were at the clinical stage IIa2, twenty at stage IIb and seven at stage IIIb. Acute hematological
toxicities included grade 3 leukopenia (8), neutropenia (5), anemia (2), grade 4 anemia (1), and grade 2 thrombocytopenia
(6). Acute non-hematological toxicities included grade 2 liver disorders (1), diarrhea (2), nausea (2), and renal
toxicity (1). There were not grade 3 or worse toxicities. 24 patients completed the treatment regimen and were evaluated
for efficacy. 23 patients (95.8%) had CR (complete response) and 1 (4.2%) had PR (partial response) (100% response rate).
The median follow-up duration was 36 months (23–39), during which three patients relapsed after the treatment. The
3-year PFS and OS rates were 87.5% and 91.7%, respectively.
Conclusions: This phase II study suggested that concurrent chemo-radiotherapy with weekly nedaplatin was effective
and safe for the treatment of advanced squamous cell carcinoma of the uterine cervix.
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Although uterine cervical carcinomas have been treated
via surgery, radiation therapy, or a combination of the
two for a long time, the treatment outcomes were poor.
In the 1990s, numerous attempts were made to improve
the prognosis of advanced uterine cervical carcinoma
with concurrent radiation therapy and chemotherapy. In
February 1999, the US National Cancer Institute (NCI)
stated that five randomized controlled trials of concur-
rent radiotherapy and chemotherapy (especially with the
use of cisplatin) demonstrated that the treatment was* Correspondence: wulingying@csco.org.cn
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creased the risk of death by 30-50% [1-5]. The concur-
rent chemo-radiotherapy (CCRT) thus became the
standard treatment of locally advanced uterine cervical
carcinoma recommended by NCI and FIGO.
However, the adverse events (especially gastrointestinal
events) associated with cisplatinare usually severe. The radi-
ation therapy leads to gastrointestinal adverse reactions as
well. The concurrent application of these two therapies sig-
nificantly aggravates gastrointestinal adverse reactions,
making it more difficult for patients to tolerate. Therefore,
a drug with mild side effect is urgently needed for the con-
current chemo-radiotherapy.
Nedaplatin is an antineoplastic drug containing a plat-
inum complex. It has better antitumor effects than cisplatind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Inclusion criteria
(i) Pathologically proven squamous cell carcinoma
(ii) Clinical FIGO stage Ib and IIa2 with bulky tumor (>40 mm,
assessed by magnetic resonance imaging) or Clinical FIGO
stage IIb, IIIa, IIIb and IVa.
(iii) No para-aortic lymph node swelling (≥10 mm) by abdominal
computed tomography
(iv) No prior radiation therapy for abdomen
(v) Performance status (Eastern Cooperative Oncology Group): 0-2
(vi) Age: 18 to 70 years old
(vii) Adequate function of bone marrow, kidney and liver
white blood cell count≥ 2500 mm3
neutrophil≥ 1000 mm3
hemoglobin≥ 8.0 g/dl
platelet count≥ 75000 mm3
creatinine≤ 2.0 mg/dl
GOT and GPT ≤ 2 times of the upper limit of normal at our
institution
T.Bil≤ 2 times of the upper limit of normal at our institution)
(viii) Written informed consent
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toxicities. A phase I clinical trial of nedaplatin showed that
the drug should be administered by intravenous infusion
with 100 mg/m2 at an interval of four weeks [6].
A phase II clinical trial using the dosage of 100 mg/m2
every four weeks showed a response rate of 46.3% (19/41
patients) in patients with uterine cervical carcinmoa [7],
which was higher than that of cisplatin (35.9%, 14/39 pa-
tients). Although it demonstrated that nedaplatin had less
severe nephrotoxicity than cisplatin, grade 3 or 4 myelosup-
pression happened in some patients (thrombocytopenia in
33.6% and leukopenia in 31.3%). The author suggested that
the use of nedaplatin requires extreme caution [7].
Nedaplatin has a higher response rate in uterine cer-
vical carcinoma than cisplatin and causes less gastro-
intestinal and renal side effects, and less fluid volume is
needed. Nedaplatin is expected to provide a longer sur-
vival and better quality of life than cisplatin.
Two other phase I clinical trials demonstrated that
nedaplatin should be administered at a dose of 30 to
35 mg/m2 every week in the concurrent Chemo-
radiotherapy [8,9]. Yoshinage et al. conducted a dose-
finding study and confirmed that the recommended dose
was 35 mg/m2 every week [8]. Another phase I study of
radiation therapy combined with nedaplatin showed that
the optimal dose of weekly nedaplatin was 30 mg/m2.
Nedaplatin could be given with minor adverse reactions
and no delay in radiation therapy [9].
We conducted a single-centered phase II study to
evaluate the tumor response rate, duration of response,
survival time and adverse events of the concurrent
chemo-radiotherapy with weekly nedaplatin in patients




Patients diagnosed with advanced squamous cell carcin-
oma of the uterine cervix were enrolled into this study
according to the following criteria (Table 1). Written in-
formed consent was obtained from all patients prior to
enrollment. The Protocol was permitted by the Ethics
Committee of the Cancer Institute and Hospital of the
Chinese Academy of Medical Sciences.
Treatment methods
Radiation therapy
External beam radiation therapy The details of the ex-
ternal beam radiation therapy using 6MV X-ray were de-
scribed below. The fraction dose was 1.8Gy, five
fractions per week. Totaling 30.6Gy using the entire pel-
vic irradiation field without central shielding was
followed by totaling 14.4Gy to 19.8Gy using the entirepelvic field with central shielding. Thus the total dose
was 45.0Gy to 50.4Gy.
Intracavitary brachytherapy Intracavitary brachyther-
apy, of which the fraction dose was 7 Gy to point A, was
given once a week for a total of five to seven times. The
total dose to point A was 35-49Gy.
Chemotherapy Nedaplatin (30 mg/m2) was dissolved in
500 ml of 0.9% sodium chloride and infused intraven-
ously over three hours. The first infusion was adminis-
tered on the starting day of the external beam radiation
therapy. The regimen was repeated weekly for six times.
The dosage of nedaplatin was decreased if grade 3 ad-
verse events occurred; nedaplatin infusion was post-
poned if grade 4 adverse events occurred.
Response and toxicity evaluation The incidence and
severity of adverse events were evaluated according to the
National Cancer Institute-Common Toxicity Criteria,
version 3.0 [10].
The tumor response was defined following the guide-
line of the Response Evaluation Criteria in Solid Tumors
(RECIST version 1.0) [11]. CR was defined as the
complete disappearance of all measurable lesions for one
month after completion of the treatment. PR was de-
fined as a more than 30% reduction in measurable le-
sions. Progressive disease (PD) was defined as a more
than 20% increase in measurable lesions or the appear-
ance on one or more new lesions. Stable disease (SD)
was defined as neither sufficient lesion shrinkage for PR,
Table 2 Patient Characteristics
Median Age, year-old (range) 50.5 (34–62)









Squamous cell carcinoma 30







Table 4 Objective Response (n = 24)
n CR (%) PR (%) SD (%) PD (%)
All stages 24 23 (95.8) 1 (4.2) 0 (0) 0 (0)
Stage IIa2 - IIb 21 20 (95.2) 1 (4.8) 0 (0) 0 (0)
Stage IIIb 3 3 (3/3) 0 (0) 0 (0) 0 (0)
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for response every four weeks by gynecological examin-
ation. In addition, radiological examinations were per-
formed prior to the treatment and one month after
completion of the treatment. The overall survival (OS)
was defined as the time from the date of registration to
death or the date of last contact. The progression free
survival (PFS) was defined as the time from the date of
registration to the date of last contact, disease progres-
sion, or death, whichever came first.Statistical design
The primary endpoint of this study was to assess the
overall response rate and the adverse events. The sec-
ondary endpoint was to assess PFS and OS. The patients
for the analysis of adverse events should receive at least
one week nedaplatin. Meanwhile, the patients for the
analysis of OS and PFS should complete the concurrent
chemo-radiotherapy. The Kaplan-Meier method was
used to estimate the overall and progression free survival
time.Table 3 Hematological Toxicities (n = 30)
G0 G1 G2 G3 G4
Leukopenia 1 6 15 8 0
Neutropenia 8 6 11 5 0
Anemia 18 7 2 2 1
Thrombocytopenia 15 8 7 0 0Results
We enrolled thirty patients in this study from April 2010 to
October 2010. Patient characteristics are presented in
Table 2. The median age was 50.5 (ranging from 34 to 62).
PS0 was 13 and PS1 was 17. Three patients were at the
clinical stage IIa2, twenty were at stage IIb and seven were
at stage IIIb.
Four patients experienced grade 2 to grade 4 myelosup-
pression after the administration of nedaplatin for one to
three weeks and the administration of nedaplatin was dis-
continued because these patients did not recover within
two weeks. One patient experienced grade 2 renal toxicity
and the administration of nedaplatin was discontinued
because the patient did not recover within two weeks. One
patient experienced grade 2 of leukopenia and nausea,
and voluntarily withdrew from the study. The above six
patients were only evaluated for toxicity, not for response.
Twenty-four patients who completed the treatment
regimen (24 out of 30, 80%) were evaluated for response.
Acute hematological toxicities were observed, including
grade 3 leukopenia in eight patients, grade 3 neutropenia in
five patients, grade 3 anemia in two patients, grade 4
anemia in one patient, and grade 2 thrombocytopenia in six
patients (Table 3).
Acute non-hematological toxicities included grade 2 liver
disorder in one patient, grade 2 diarrhea in two patients,
grade 2 nausea in two patients, and grade 2 renal toxicity in
one patient. No patient experienced grade 3 or greater
acute non-hematological toxicities.
Patients who completed the treatment regimen were
evaluated for response rate one month after completion
of the treatment. Twenty-three patients (95.8%) had CR
and one (4.2%) had PR (Table 4).
The median follow-up duration was 36 months
(range, 23–39), during which three patients relapsed
after the treatment. Two patients with complete re-
sponse relapsed (one patient relapsed inside the radi-
ation field and the other in the lung). The only
patient with partial response underwent three courses
of chemotherapy shortly after completion of the treat-
ment, and relapsed in the lung twenty months after
the treatment. The 3-year PFS and OS rates were
87.5% and 91.7%, respectively (Figure 1, Figure 2).
The 3-year PFS rates were 100.0% (3/3), 88.9% and
66.7% (2/3) in patients with stage IIa, IIb and IIIb, re-
spectively. Meanwhile, the 3-year OS rates were
100.0% (3/3), 88.9% and 100.0% (3/3) in patients at
Figure 1 3-Year progression-free survival rate. The median follow-up duration was 36 months (range: 23–39).
Figure 2 3-Year overall survival rate. The median follow-up duration was 36 months (range: 23–39).
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Table 5 3-Year PFS and OS Rates
No. of patients The 3-year PFS (%) P-value The 3-year OS (%) P-value
All patients 24 87.5 - 91.5 -
Stage
IIa2 3 3/3 3/3
IIb 18 88.9 88.9
IIIb 3 2/3 0.360 3/3 0.710
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not significantly different (Table 5).
Discussion
The concurrent chemo-radiotherapy (CCRT) with cisplatin
is currently the standard treatment for locally advanced
uterine cervical carcinoma. However, the radiotherapy
causes gastrointestinal adverse reactions, and cisplatin is as-
sociated with severe gastrointestinal adverse reactions. The
CCRT thus inevitably aggravates gastrointestinal adverse
reactions, which makes it more difficult for patients to tol-
erate. Cisplatin has severe renal toxicity as well. Therefore,
many researchers tried to replace cisplatin with other
agents as the radio-sensitizing agent in the CCRT for locally
advanced uterine cervical carcinoma.
Nedaplatin (cis-diammine-glycoplatinum), a derivative of
cisplatin, was developed in 1983 by Shionogi Pharmaceut-
ical Company to provide a treatment with similar efficacy
as cisplatin but less renal and gastrointestinal toxicities [12].
The preclinical evaluation of nedaplatin in cervical cancer
demonstrated similar antitumor activity as cisplatin [13,14].
The incidence of nephrotoxicity was lower than that of cis-
platin, due to the difference in drug distribution in the kid-
ney. After the administration of the same dose, the amount
of nedaplatin that accumulated in the rat kidney was ap-
proximately 40% of that of cisplatin, which explains why
nedaplatin has less nephrotoxicity than cisplatin [15,16].
The radio-sensitizing properties of nedaplatin in the set-
ting of CCRT for advanced uterine cervical carcinoma have
been evaluated in two Phase I [8,9] studies, in which weekly
30–35 mg/m2 nedaplatin was recommended.
In a phase II study [17] of CCRT with nedaplatin for ad-
vanced uterine cervical carcinoma, the results showed that
the response rate was 100% (80% for CR (8/10), and 20%
for PR (2/10). In another phase II study [18] of CCRT with
nedaplatin for advanced uterine cervical carcinoma,
Yokoyama Y et al. reported that 40 of 45 enrolled patients
completed the treatment. The response rate was 100%
(90% had CR and 10% had PR). The median follow-up dur-
ation was 29 months (range: 8–52), the 3-year PFS and OS
rates were 58.7% and 78.0% respectively. The response rate
in this study was comparable to those in the two studies
above. The 3-year PFS and OS rates in this study were
higher than those in Yokoyama's report. The reason might
be a lower proportion of patients at stage IIIb (12.5%).In this study, a total of 30 patients were treated with
radiotherapy plus concurrent chemotherapy. The dosage
of nedaplatin chosen was weekly 30 mg/m2. Grade 3
leukopenia, neutropenia, anemia and thrombocytopenia
were found in 26.7%, 16.7%, 6.7% and 0.0% of enrolled
patients, respectively. Only one patient experienced grade 4
anemia (Table 3). There was no grade 3 or 4 non-
hematological toxicity. 6 (20.0%) of the 30 enrolled patients
withdrew from the trial due to myelosuppression, renal tox-
icity and nausea. The completion rate was 80% and the de-
layed duration was a maximum of 1 week. The complete
response rate was 95.8% and all of the patients had a suc-
cessful response. The 3-year PFS and OS rates were 87.5%
and 91.5%, respectively. In addition, 80% of the enrolled pa-
tients completed the study with grade 4 hematological tox-
icities occurred in a few patients (3.3%), which indicated
that weekly nedaplatin of 30 mg/m2 with concurrent radio-
therapy was an effective and well-tolerated regimen for ad-
vanced uterine cervical carcinoma.
One of the limitations of this study was the small pa-
tient sample size. However, the results are sufficient to
warrant further research. A randomized phase III study
of this regimen were needed to validate whether neda-
platin in concurrent chemo-radiotherapy is a better
choice than cisplatin with respect to the survival of pa-
tients with advanced squamous cell carcinoma of the
uterine cervix.
Conclusion
This phase II study suggested that concurrent chemo-
radiotherapy with weekly nedaplatin was effective and safe
for the treatment of advanced squamous cell carcinoma of
the uterine cervix.
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